‘Highest response rate ever reported’ in relapsed mantle cell lymphoma

A good summary if a bit technical of recent findings on new mantle cell lymphoma treatments from the American Society of Hematology annual meeting. Two new treatments for relapsed MCL with encouraging results: Ibrutinib Bortezomib (Velcade) – updating on longer-term outcomes No sense from the article how this success rate compares to other approaches (e.g., [...]